{"count":5,"next":null,"previous":null,"results":[{"url":"https://lda.gov/api/v1/filings/c5955a4e-db81-40c3-9026-e0f813d40dda/","filing_uuid":"c5955a4e-db81-40c3-9026-e0f813d40dda","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/c5955a4e-db81-40c3-9026-e0f813d40dda/print/","filing_document_content_type":"text/html","income":null,"expenses":"80000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Jennie Skelton","dt_posted":"2026-10-15T18:20:51-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1455 Pennsylvania Avenue NW, Suite 1150","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":401109501,"url":"https://lda.gov/api/v1/registrants/401109501/","house_registrant_id":76992,"name":"RARE DISEASE COMPANY COALITION","description":null,"address_1":"1455 Pennsylvania Avenue NW, Suite 1150","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JENNIE UNGER SKELTON","contact_telephone":"+1 415-903-2800","dt_updated":"2026-07-23T14:09:47.139641-04:00"},"client":{"id":66024,"url":"https://lda.gov/api/v1/clients/66024/","client_id":66024,"name":"RARE DISEASE COMPANY COALITION","general_description":"Healthcare","client_government_entity":null,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2025-03-20"},"lobbying_activities":[{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"H.R. 10359 - Priority Review Voucher (PRV) permanence bill H.R. 1532/S. 822 - Scientific EXPERT Act 42 CFR Part 513 - Rare disease exemption from GLOBE mode/final rule 91 FR 18183 - Clarification of orphan exemption from 232 pharmaceutical tariffs H.R. 1414 - Orphan Drug Tax Credit","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":149523,"prefix":null,"prefix_display":null,"first_name":"YOKO","nickname":null,"middle_name":null,"last_name":"ROSENBAUM","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":153641,"prefix":null,"prefix_display":null,"first_name":"GABBI","nickname":null,"middle_name":null,"last_name":"SALMON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/712c3c0b-0f09-4eeb-9605-0230881b4aae/","filing_uuid":"712c3c0b-0f09-4eeb-9605-0230881b4aae","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/712c3c0b-0f09-4eeb-9605-0230881b4aae/print/","filing_document_content_type":"text/html","income":null,"expenses":"60000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Annie Kennedy","dt_posted":"2026-10-16T08:54:26-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1012 14th NW, Suite 500","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":401106105,"url":"https://lda.gov/api/v1/registrants/401106105/","house_registrant_id":null,"name":"RARE FOUNDATION (FORMERLY KNOWN AS EVERYLIFE FOUNDATION FOR RARE DISEASES)","description":"Nonprofit, nonpartisan organization dedicated to empowering rare disease patient community","address_1":"1012 14th NW, Suite 500","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ANNIE KENNEDY","contact_telephone":"+1 202-697-7273","dt_updated":"2026-10-16T13:50:48.525272-04:00"},"client":{"id":210900,"url":"https://lda.gov/api/v1/clients/210900/","client_id":12,"name":"RARE FOUNDATION (FORMERLY KNOWN AS EVERYLIFE FOUNDATION FOR RARE DISEASES)","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2021-04-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"S. 822, H.R. 1532 - Scientific EXPERT Act of 2025; H.R. 4709 - Newborn Screening Saves Lives Reauthorization Act of 2025; FY 2027 Appropriations; FDA user fee reauthorization; H.R. 7118 - Genomic Answers for Children's Health Act; H.R. 5509, S. 2903 - Safe Step Act; H.R. 1414 - Cameron's Law; H.R. 10359 - Priority for Pediatric Cures Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":101949,"prefix":null,"prefix_display":null,"first_name":"JAMIE","nickname":null,"middle_name":null,"last_name":"SULLIVAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":101951,"prefix":null,"prefix_display":null,"first_name":"DYLAN","nickname":null,"middle_name":null,"last_name":"SIMON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/b5728520-391e-471c-8a9b-7cfc5a53ef4b/","filing_uuid":"b5728520-391e-471c-8a9b-7cfc5a53ef4b","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/b5728520-391e-471c-8a9b-7cfc5a53ef4b/print/","filing_document_content_type":"text/html","income":"50000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Mary Beth Savary Taylor","dt_posted":"2026-10-19T16:48:58-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"601 13th St. NW","registrant_address_2":"Suite 250 N","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":293335,"url":"https://lda.gov/api/v1/registrants/293335/","house_registrant_id":37338,"name":"THE NICKLES GROUP, LLC","description":"Consulting firm.","address_1":"601 13th St. NW","address_2":"Suite 250 N","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"KATHLEEN MCGHEE","contact_telephone":"+1 202-742-6990","dt_updated":"2026-07-06T11:19:03.627222-04:00"},"client":{"id":178567,"url":"https://lda.gov/api/v1/clients/178567/","client_id":1005344,"name":"OMEROS CORPORATION","general_description":"Biopharmaceutical company.","client_government_entity":false,"client_self_select":null,"state":"WA","state_display":"Washington","country":"US","country_display":"United States of America","ppb_state":"WA","ppb_state_display":"Washington","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2017-02-01"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues involving rare disease therapies.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":26331,"prefix":null,"prefix_display":null,"first_name":"MARY","nickname":null,"middle_name":"BETH","last_name":"SAVARY TAYLOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":103387,"prefix":null,"prefix_display":null,"first_name":"BRETT","nickname":null,"middle_name":null,"last_name":"BAKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to rare pediatric disease and Priority Review Vouchers (PRVs). H.R. 10359, Priority for Pediatric Cures Act.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":26331,"prefix":null,"prefix_display":null,"first_name":"MARY","nickname":null,"middle_name":"BETH","last_name":"SAVARY TAYLOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":103387,"prefix":null,"prefix_display":null,"first_name":"BRETT","nickname":null,"middle_name":null,"last_name":"BAKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/8c0099df-681c-43f5-9ba7-c5bc563458d4/","filing_uuid":"8c0099df-681c-43f5-9ba7-c5bc563458d4","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/8c0099df-681c-43f5-9ba7-c5bc563458d4/print/","filing_document_content_type":"text/html","income":null,"expenses":"100000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Christopher Porter","dt_posted":"2026-10-19T20:44:28-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"3611 Valley Centre Drive","registrant_address_2":"Suite 300","registrant_different_address":true,"registrant_city":"San Diego","registrant_state":"CA","registrant_zip":"92130","registrant":{"id":401104190,"url":"https://lda.gov/api/v1/registrants/401104190/","house_registrant_id":null,"name":"TRAVERE THERAPEUTICS","description":"Pharmaceuticals","address_1":"3611 Valley Centre Drive","address_2":"Suite 300","address_3":null,"address_4":null,"city":"San Diego","state":"CA","state_display":"California","zip":"92130","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CHRISTOPHER PORTER","contact_telephone":"+1 877-969-7879","dt_updated":"2026-07-20T10:56:00.116563-04:00"},"client":{"id":200929,"url":"https://lda.gov/api/v1/clients/200929/","client_id":12,"name":"TRAVERE THERAPEUTICS","general_description":"Biopharmaceuticals","client_government_entity":false,"client_self_select":true,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2016-08-15"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act; end-stage renal disease policy and rare kidney disease; HR 10571, the Surge to Save Newborns Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64866,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"PORTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141299,"prefix":null,"prefix_display":null,"first_name":"ROSE","nickname":null,"middle_name":null,"last_name":"GALLAGHER","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64866,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"PORTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141299,"prefix":null,"prefix_display":null,"first_name":"ROSE","nickname":null,"middle_name":null,"last_name":"GALLAGHER","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA); H.R. 10359, Priority for Pediatric Cures Act to make PRV permanent","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64866,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"PORTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141299,"prefix":null,"prefix_display":null,"first_name":"ROSE","nickname":null,"middle_name":null,"last_name":"GALLAGHER","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Medicare and Medicaid related provisions in H.R.1, One Big Beautiful Bill Act.H.R. 9509, the Kidney Disease Education Expansion Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64866,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"PORTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141299,"prefix":null,"prefix_display":null,"first_name":"ROSE","nickname":null,"middle_name":null,"last_name":"GALLAGHER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"S.1040, to prohibit product hopping and for other purposes; proposals regarding patent thickets. S. 2658, Medication Affordability and Patent Integrity Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64866,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"PORTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141299,"prefix":null,"prefix_display":null,"first_name":"ROSE","nickname":null,"middle_name":null,"last_name":"GALLAGHER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related implementation provisions in H.R.1, One Big Beautiful Bill Act; pharmaceutical tariffs, specifically related to orphan drugs","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64866,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"PORTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141299,"prefix":null,"prefix_display":null,"first_name":"ROSE","nickname":null,"middle_name":null,"last_name":"GALLAGHER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/7d8346b9-2be5-4133-8ef2-6927bb5c2456/","filing_uuid":"7d8346b9-2be5-4133-8ef2-6927bb5c2456","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/7d8346b9-2be5-4133-8ef2-6927bb5c2456/print/","filing_document_content_type":"text/html","income":"50000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Tracy Spicer","dt_posted":"2026-10-20T16:02:50-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"401 9th St. NW","registrant_address_2":"Suite 720","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":72111,"url":"https://lda.gov/api/v1/registrants/72111/","house_registrant_id":35940,"name":"AVENUE SOLUTIONS","description":"Government representation","address_1":"401 9th St. NW","address_2":"Suite 720","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"AMY TEJRAL","contact_telephone":"+1 202-347-9848","dt_updated":"2026-07-30T13:56:38.410932-04:00"},"client":{"id":165820,"url":"https://lda.gov/api/v1/clients/165820/","client_id":1004443,"name":"OMEROS CORPORATION","general_description":"Biopharmaceutical company","client_government_entity":false,"client_self_select":null,"state":"WA","state_display":"Washington","country":"US","country_display":"United States of America","ppb_state":"WA","ppb_state_display":"Washington","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-02-28"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to Pediatric Review Voucher (PRV); H.R. 10359, Priority for Pediatric Cures Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":23462,"prefix":null,"prefix_display":null,"first_name":"TRACY","nickname":null,"middle_name":null,"last_name":"SPICER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149107,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"FUENTES","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}]}